|
Volumn 31, Issue 3, 1995, Pages 453-459
|
Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: A report of radiation therapy oncology group (RTOG) 83-02
a b c d e b f |
Author keywords
Hyperfractionated radiation therapy; Malignant gliomas; Quality of life
|
Indexed keywords
CARMUSTINE;
ADULT;
ARTICLE;
CANCER CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL FEATURE;
CLINICAL TRIAL;
DISEASE SEVERITY;
FEMALE;
FUNCTIONAL ASSESSMENT;
GLIOBLASTOMA;
HISTOLOGY;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MEDICAL RECORD;
NEUROTOXICITY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RADIATION DOSE;
ADULT;
AGED;
BRAIN NEOPLASMS;
CARMUSTINE;
COMBINED MODALITY THERAPY;
FEMALE;
GLIOMA;
HUMAN;
MALE;
MIDDLE AGE;
QUALITY OF LIFE;
RADIOTHERAPY DOSAGE;
SUPPORT, U.S. GOV'T, P.H.S.;
SURVIVAL ANALYSIS;
|
EID: 0028813901
PISSN: 03603016
EISSN: None
Source Type: Journal
DOI: 10.1016/0360-3016(95)93160-9 Document Type: Article |
Times cited : (54)
|
References (14)
|